Core Insights - Esperion is hosting a virtual key opinion leader (KOL) event to discuss the challenges of statin intolerance and its impact on patient outcomes, emphasizing the company's commitment to addressing this unmet need [1][2] Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for patients at risk of cardiovascular disease, specifically targeting elevated low-density lipoprotein cholesterol (LDL-C) [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for this patient population, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [3] Industry Context - Cardiovascular disease is the leading cause of morbidity and mortality globally, with nearly 20% of patients discontinuing statin therapy within the first year, often without transitioning to alternative treatments [2] - The urgent need for innovative solutions in cardiovascular care is highlighted, as patients who discontinue statin therapy remain vulnerable to serious cardiovascular events [2]

Core Insights - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of September 5, 2025 [1] Group 1: Esperion Therapeutics Inc (ESPR) - Esperion Therapeutics reported better-than-expected second-quarter financial results, highlighting a 15% sequential quarterly growth and 42% year-over-year growth in net U.S. product sales [7] - The company's stock surged approximately 56% over the past month, reaching a 52-week high of $3.94 [7] - The RSI value for Esperion is 85.7, indicating it is considered overbought [7] Group 2: Nuvation Bio Inc (NUVB) - Nuvation Bio reported an in-line loss for the second quarter but noted the FDA approval of IBTROZI, marking its transition into a commercial-stage company [8] - The stock gained around 44% over the past month, with a 52-week high of $3.48 [8] - The RSI value for Nuvation Bio is 81.8, also indicating it is considered overbought [8]